Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 18/20 | 0.54 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | HTR1D | P28221 | 1/20 | 0.43 |
| ▸ | HTR1B | P28222 | 1/20 | 0.43 |
| ▸ | HTR1F | P30939 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.40 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3413346 | 0.82 | HTR6 (0.46) | HTR6DRD2HTR2A | |
| SCHEMBL19216921 | 0.79 | HTR6 (0.52) | HTR6HTR1DHTR1BDRD3ALK | |
| SCHEMBL3052460 | 0.79 | HTR6 (0.64) | HTR6DRD2HTR1AHTR1DHTR1B | |
| SCHEMBL3619076 | 0.76 | HTR6 (0.52) | HTR6 | |
| SCHEMBL31634100 | 0.73 | HTR6 (0.49) | HTR6 | |
| SCHEMBL1973755 | 0.71 | HTR6 (0.51) | HTR6DRD2HTR1AHTR1DHTR1B | |
| SCHEMBL4797587 | 0.71 | AKR1C3 (0.48) | HTR6 | |
| SCHEMBL4782100 | 0.71 | HTR6 (0.47) | HTR6DRD2HTR1AHTR7HTR2A | |
| SCHEMBL4367746 | 0.71 | HTR6 (0.51) | HTR6HTR1DHTR1BDRD3ALK | |
| SCHEMBL3204417 | 0.70 | HTR6 (1.00) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816328-B2 | Substituted fused heterocyclic C-glycosides | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-19 | — | — | US | disclosed |
| US-20100004160-A1 | SUBSTITUTED FUSED HETEROCYCLIC C-GLYCOSIDES | RYBCZYNSKI PHILIP | 2010-01-07 | — | — | US | disclosed |
| US-20090105162-A1 | SUBSTITUTED FUSED HETEROCYCLIC C-GLYCOSIDES | RYBCZYNSKI PHILIP | 2009-04-23 | — | — | US | disclosed |
| US-7482330-B2 | Substituted fused heterocyclic C-glycosides | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-01-27 | — | — | US | disclosed |
| US-20060229260-A1 | Substituted fused heterocyclic C-glycosides | Tanabe Pharma Corporation (JP) | 2006-10-12 | — | — | US | disclosed |
| US-7094763-B2 | Substituted fused heterocyclic C-glycosides | JANSSEN PHARACEUTICA, N.V. (BE) | 2006-08-22 | — | — | US | disclosed |
| US-20050037980-A1 | Substituted fused heterocyclic C-glycosides | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004160-A1 | SUBSTITUTED FUSED HETEROCYCLIC C-GLYCOSIDES | UGCG, UGGT1, GCG | HTR6 4328/4885DRD2 4433/4885HTR1A 4358/4885 |
| US-20060229260-A1 | Substituted fused heterocyclic C-glycosides | UGCG, UGGT1, GCG | HTR6 4328/4885DRD2 4433/4885HTR1A 4358/4885 |
| US-20090105162-A1 | SUBSTITUTED FUSED HETEROCYCLIC C-GLYCOSIDES | UGCG, UGGT1, GCG | HTR6 4328/4885DRD2 4433/4885HTR1A 4358/4885 |
| US-20050037980-A1 | Substituted fused heterocyclic C-glycosides | UGCG, UGGT1, GCG | HTR6 4328/4885DRD2 4433/4885HTR1A 4358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.